NCT00417261View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

April 30, 2008

Conditions
Healthy
Interventions
DRUG

ATF936

DRUG

AXT914

Trial Locations (1)

07936-1080

Novartis Investigative Site, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00417261 - Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects. | Biotech Hunter | Biotech Hunter